December 21, 2021 7:36am

Sector stock’s rise, stock’s fall – forget the market, focus on the Christmas holiday coming

Pre-open indications: 7 SELLs into Strength and 1 BUY

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing! I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.88% (+307 points), S&P futures are UP +0.96% (+44 points) and NASDAQ futures are UP +1.09% (+170 points)

 

Futures are pointing to a higher open and a rebound for stocks on Tuesday,

European markets climbed retracing much of Monday’s losses,

Asia-Pacific markets rose as investors monitored the omicron Covid variant.

 

Henry’omics:

A losing index session with low trading volume ahead of the holidays, the Dow dropped 433 points (-1.23%), the S&P 500 52.62 points (-1.14%) and the Nasdaq 188.74 points (-1.24%) on Monday.

The sector ended neutral with an advance/decline line of 16/16, 2 flats and 1 acquired.

The omicron surge has kept investors on edge with the variant now found in at least 43 U.S. states and 90 countries.

  • Variant is now dominant US strain and causing 73% of new infections

 

If you didn’t remember what happen at Monday night’s close, you won’t be prepared for today’s session:

Monday’s evening’s recap: “from the oversold mud to a draw in the daily share pricing tug-of-war. An oversold “Santa Rally” yet, I had written this a.m., I was NOT in a Santa Mood” and will stay that way until years-end” … https://www.regmedinvestors.com/articles/12234

Q4: December, 6 negative, 1 neutral and 7 positive closes

  • November, 1 holiday 5 positive and 16 negative close to date
  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Probabilities versus aftermarket/pre-open share pricing indication moves:

SELL into Strength and the Bounce:

  • Alnylam Pharmaceuticals (ALNY),
  • Ultragenyx (RARE),
  • Fate Therapeutics (FATE),
  • BioLife Solutions (BLFS),
  • CRISPR Therapeutics (CRSP),
  • Intellia Therapeutics (NTLA),

Never forget: Biostage (OTCQB: BSTG) closed up +$0.53 with 425 shares traded after Friday’s -$0.37 after Thursday’s flat $0.00 with 371 shares traded after Wednesday closed -$0.00 with 3,281 shares traded and last Tuesday closed flat with 500 shares traded. Notice how the shares traded with and without the manipulated share pricing by volume stimulation.

 

BUY:

Editas Medicine (EDIT)

 

The BOTTOM LINE: An up-tight market correction sends a clear signal and I’m maintaining a “get out of Dodge” position re sector equities.

The cell and gene therapy sector has a downside bias and is dangerous “plot; to “play” in. It's an environment that lures investors in, only to sell off sharply again.

During extended periods of volatility and weakness, it's best to avoid most breakouts, unless it's a perfect set up and breakout. The alternating selling sessions in the sector should give you pause. I

If you want to buy, focus only on stocks showing exceptional fundamental and technical strength.

The risk level is very elevated at this point and there's no need to rush back into the market.

It's perfectly acceptable to watch from the sidelines and wait for the market to prove itself amid the recent losses.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis”.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.